IN2014DN08939A - - Google Patents

Info

Publication number
IN2014DN08939A
IN2014DN08939A IN8939DEN2014A IN2014DN08939A IN 2014DN08939 A IN2014DN08939 A IN 2014DN08939A IN 8939DEN2014 A IN8939DEN2014 A IN 8939DEN2014A IN 2014DN08939 A IN2014DN08939 A IN 2014DN08939A
Authority
IN
India
Prior art keywords
low
therapeutic compounds
low solubility
formulations
basicity
Prior art date
Application number
Inventor
David E Pereira
Sara Wu
Prabhavathi Fernandes
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of IN2014DN08939A publication Critical patent/IN2014DN08939A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Pharmaceutical compositions adapted for the parenteral administration including intravenous administration of triazole containing macrolide antibiotics and methods or their use in the treatment of bacterial protozoal and other infections are described herein. Also described herein are solid solution and liquid formulations for such other therapeutic compounds that are characterized by low solubility and/or low basicity. It has been surprisingly discovered that the formulations described herein that include of one or more lactic acids one or more amino acids or combinations thereof including any pharmaceutically acceptable salts of the foregoing are useful for the parenteral delivery of such low solubility and/or low basicity therapeutic compounds.
IN8939DEN2014 2012-03-27 2013-03-27 IN2014DN08939A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616196P 2012-03-27 2012-03-27
US201361783026P 2013-03-14 2013-03-14
PCT/US2013/034179 WO2013148891A1 (en) 2012-03-27 2013-03-27 Parenteral formulations for administering macrolide antibiotics

Publications (1)

Publication Number Publication Date
IN2014DN08939A true IN2014DN08939A (en) 2015-05-22

Family

ID=49261221

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8939DEN2014 IN2014DN08939A (en) 2012-03-27 2013-03-27

Country Status (15)

Country Link
US (2) US10188674B2 (en)
EP (1) EP2830632A4 (en)
JP (2) JP6208742B2 (en)
KR (1) KR20140139083A (en)
CN (1) CN104470527B (en)
AU (1) AU2013239696C1 (en)
CA (1) CA2868262A1 (en)
HK (1) HK1205939A1 (en)
IL (2) IL234769A (en)
IN (1) IN2014DN08939A (en)
MX (1) MX2014011537A (en)
NZ (1) NZ700182A (en)
RU (1) RU2658050C2 (en)
SG (1) SG11201405895UA (en)
WO (1) WO2013148891A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3738591A3 (en) 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Novel antibacterial agents
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US9072759B2 (en) 2008-10-24 2015-07-07 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (en) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedures for the treatment of malaria, tuberculosis and MAC diseases
ES2636948T3 (en) 2010-05-20 2017-10-10 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates for them
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
IN2014DN08939A (en) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CN105163785A (en) 2013-03-14 2015-12-16 森普拉制药公司 Methods for treating respiratory diseases and formulations therefor
RU2015138797A (en) 2013-03-15 2017-04-24 Семпра Фармасьютикалс, Инк. CONVERGENT METHODS FOR PRODUCING MACROLIDE ANTIBACTERIAL AGENTS
MX377459B (en) 2013-04-04 2025-03-10 Harvard College MACROLIDES AND METHODS FOR THEIR PREPARATION AND USE.
WO2016057798A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
CN107530365A (en) 2015-03-25 2018-01-02 哈佛大学的校长及成员们 Macrolide of desosamine sugar with modification and application thereof
BR112019017223A2 (en) * 2017-02-17 2020-04-14 Cempra Pharmaceuticals Inc macrolides containing triazole and their ophthalmic uses
CN109394200B (en) * 2018-12-16 2021-10-19 冯兴怀 Microcirculation pulse blood flow monitoring system and method for liquid treatment and volume management

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1354753A (en) 1919-02-11 1920-10-05 E M Lannes Portable building
US2180006A (en) 1936-09-09 1939-11-14 Eastman Kodak Co Process for the separation and refining of amines
GB891817A (en) * 1959-04-07 1962-03-21 Upjohn Co Improvements in or relating to injectable tetracyclic preparations
GB891617A (en) 1959-09-02 1962-03-14 Clifford Brothers Ltd Lever handle for operating a latch or the spring bolt in a lock
US3843787A (en) 1969-01-15 1974-10-22 Pierrel Spa Water soluble derivative of erythromycin
US3668282A (en) 1970-05-08 1972-06-06 Stauffer Chemical Co Stabilized mixture employing n-(beta-0,0-dialkyldithiophosphoryl) aryl sulfonamides
US3843767A (en) 1972-03-27 1974-10-22 Du Pont Process for treating fluophosphate ores
SE458505B (en) * 1979-07-10 1989-04-10 Lepetit Spa APPLICATION OF RIFAMYCIN SV AND SALTS THEREOF PREPARING A PREPARATION FOR TREATMENT OF REUMATOID ARTHRITIS AND CERTAIN SALTS AND THEIR PREPARATION
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS59104326A (en) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd Stable oral preparation of macrolide antibiotic substance, and method for stabilizing the same
JPS59175414A (en) 1983-03-23 1984-10-04 Toyo Jozo Co Ltd Stable oral preparation of macrolide antibiotic substance and method for stabilizing the same
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
KR960000434B1 (en) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 Erythromycin A derivatives and preparation method thereof
HU198913B (en) 1987-09-03 1989-12-28 Pliva Pharm & Chem Works Process for producing 10-dihydro-10-deoxo-11-aza-erythronolide a-derivatives and pharmaceutical compositions containing them as active components
BE1001869A3 (en) * 1988-10-12 1990-04-03 Franz Legros METHOD OF PACKAGING liposomal AMINOGLUCOSIDIQUES ANTIBIOTICS IN PARTICULAR THE GENTAMYCIN.
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
TW271400B (en) 1992-07-30 1996-03-01 Pfizer
FR2697524B1 (en) 1992-11-05 1994-12-23 Roussel Uclaf New erythromycin derivatives, their preparation process and their use as drugs.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
JPH07126172A (en) 1993-11-05 1995-05-16 Genichiro Soma Lps-containing anti-mrsa agent and anti-mrsa agent for animal
FR2718450B1 (en) 1994-04-08 1997-01-10 Roussel Uclaf New erythromycin derivatives, their preparation process and their use as drugs.
FR2719587B1 (en) 1994-05-03 1996-07-12 Roussel Uclaf New erythromycin derivatives, their preparation process and their use as drugs.
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (en) 1995-10-09 1997-12-19 Roussel Uclaf NOVEL DERIVATIVES OF 5-0-DESOSAMINYL 6-O-METHYL ERYTHRONOLIDE A, THEIR PREPARATION PROCESS AND THEIR APPLICATION TO THE PREPARATION OF BIOLOGICALLY ACTIVE PRODUCTS
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (en) 1995-12-22 1998-01-30 Roussel Uclaf NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
FR2745290B1 (en) 1996-02-28 1998-04-03 Roussel Uclaf NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
DE69733723T2 (en) 1996-09-04 2006-04-20 Abbott Laboratories, Abbott Park 6-o-substituted ketolides with antibacterial activity
IL130300A0 (en) 1996-12-13 2000-06-01 Lilly Co Eli Inhibitors of the enzymatic activity of PSA
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000086A (en) 1997-06-11 1999-03-08 Pfizer Prod Inc DERIVATIVES OF 9 - DESOFO - 9 AZA - 9A - HOMOERITROMICINA A - C - 4 SUBSTITUTED.
TR199902995T2 (en) 1997-06-11 2000-02-21 Pfizer Products Inc. 9-Oxime erythromycin derivatives
HN1998000074A (en) 1997-06-11 1999-01-08 Pfizer Prod Inc DERIVATIVES FROM MACROLIDES C-4 SUBSTITUTED
HN1998000159A (en) 1997-10-29 1999-02-09 Monsanto Co DERIVATIVES OF 9- AMINO - 3 CETO ERITROMICINA
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
ATE464900T1 (en) 1998-03-26 2010-05-15 Astellas Pharma Inc SUSTAINED-RELEASE PREPARATION WITH MACROLIDS SUCH AS TACROLIMUS
FR2777282B1 (en) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc NEW DERIVATIVES OF 2-FLUORO 3-DE ((2,6-DIDEOXY 3-C-METHYL 3-0-METHYL-ALPHA-L-RIBOHEXOPYRANOSYL) OXYL) 6-O-METHYL 3-OXO ERYTHROMYCIN, THEIR PREPARATION PROCESS AND THEIR APPLICATION TO THE SYNTHESIS OF ACTIVE INGREDIENTS OF MEDICINES
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (en) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc NOVEL DERIVATIVES OF ERYTHROMYCIN, PROCESS FOR PREPARING THEM AND THEIR APPLICATION AS MEDICAMENTS
KR100317907B1 (en) 1998-11-24 2001-12-24 김 완 주 Novel Intermediates, process for preparing macrolide antibiotic agent therefrom
FR2786188B1 (en) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
WO2000034297A1 (en) 1998-12-10 2000-06-15 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
ID30233A (en) 1999-01-27 2001-11-15 Pfizer Prod Inc ANTIBIOTICS OF TETOLIDA
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2789392B1 (en) 1999-02-04 2001-10-05 Hoechst Marion Roussel Inc NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
JP2000351794A (en) 1999-04-08 2000-12-19 Hokuriku Seiyaku Co Ltd Erythromycin derivative
AR023264A1 (en) 1999-04-08 2002-09-04 Hokuriku Pharmaceutical ERYTHROMYCIN DERIVATIVES
KR20020007374A (en) 1999-04-16 2002-01-26 추후제출 Macrolide antiinfective agents
US6399582B1 (en) 1999-04-16 2002-06-04 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (en) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
AU3337900A (en) 1999-08-09 2001-03-05 Eric Au An apparatus for treating wastewater
US6096922A (en) 1999-11-01 2000-08-01 Air Products And Chemicals, Inc. Process for the synthesis of dialkyl, diaryl, and arylalkyl aminosulfur trifluorides
KR100336447B1 (en) 1999-11-24 2002-05-15 민경윤 Improved method of preparing clarithromycin
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2001261694A (en) 2000-03-06 2001-09-26 Pfizer Prod Inc Ketolide antibiotic
ES2242668T3 (en) 2000-03-15 2005-11-16 Hanmi Pharm. Co., Ltd. METHOD FOR OBTAINING CLARITROMYCIN IN CRYSTALS OF FORM II.
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
FR2821747B1 (en) 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques SUSPENSION OF TELITHROMYCIN WITH A MASK TASTE
EP1320355B1 (en) 2001-05-18 2006-04-05 Chiron Corporation System for delivering a tobramycin formulation
FR2826274B1 (en) 2001-06-21 2003-09-26 Aventis Pharma Sa PHARMACEUTICAL FORMULATION FOR MASK TASTE AND METHOD FOR PREPARING THE SAME
EP1404693A2 (en) 2001-07-03 2004-04-07 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
WO2003072141A1 (en) 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
WO2003101972A1 (en) 2002-05-30 2003-12-11 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
BR0311883A (en) 2002-06-17 2005-04-05 Epigenesis Pharmaceuticals Llc Sealed container, kit, and methods for the prophylaxis or treatment of asthma, for the prophylaxis or treatment of chronic obstructive pulmonary disease, for the reduction or exhaustion of adenosine in a patient's tissue and for the prophylaxis or treatment of an associated disorder or condition. with high adenosine levels or adenosine sensitivity in a tissue of the patient
WO2004005310A2 (en) 2002-07-08 2004-01-15 Pliva-Istrazivacki Institut D.O.O. New compounds, compositions and methods for treatment of inflammatory diseases and conditions
US20040013737A1 (en) 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (en) 2002-10-29 2004-04-30 Zambon Spa 9A-AZALIDS WITH ANTI-INFLAMMATORY ACTIVITY.
EP3738591A3 (en) 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Novel antibacterial agents
EP1618119A2 (en) 2003-04-25 2006-01-25 Chiron Corporation Pyridyl substituted ketolide antibiotics
EP1618120A2 (en) 2003-04-25 2006-01-25 Chiron Corporation Novel ketolide derivatives
PL1628989T3 (en) 2003-05-13 2007-05-31 Glaxo Group Ltd Novel 14 and 15 membered-ring compounds
US20050014706A1 (en) 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
GB0402578D0 (en) 2004-02-05 2004-03-10 Cambridge Theranostics Ltd Methods of treatment of atherosclerosis
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
AU2005238313A1 (en) 2004-04-28 2005-11-10 Alembic Limited Process for the preparation of telithromycin
CA2566085A1 (en) 2004-05-06 2005-11-17 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O Ester linked macrolides useful for the treatment of microbial infections
JP2008508322A (en) 2004-07-28 2008-03-21 ランバクシー ラボラトリーズ リミテッド Ketolide derivatives as antibacterial agents
GB0424958D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
GB0424959D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
PL1836211T3 (en) 2004-12-21 2010-07-30 Pfizer Prod Inc Macrolides
ES2371931T3 (en) 2005-01-14 2012-01-11 Glaxo Group Limited MACROLID COMPOUNDS CONTAINING BIOTIN AND GROUP WITH PHOTO-AFFINITY FOR THE IDENTIFICATION OF THE MACROLID DIANA.
ATE477805T1 (en) 2005-01-14 2010-09-15 Glaxosmithkline Zagreb 9A-CARBAMOYL-Y-AMINOPROPYL AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL AZALIDES WITH ANTIMALARIA ACTIVITY
WO2006087642A2 (en) 2005-01-14 2006-08-24 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9a-carbamoyl and thiocarbamoyl azalides with antimalarial activity
JP2008534504A (en) 2005-03-22 2008-08-28 アゼヴァン ファーマスーティカルズ，インコーポレイテッド Β-Lactamyl alkanoic acid for treating premenstrual disorders
JP2008542296A (en) 2005-05-25 2008-11-27 サートリス ファーマシューティカルズ， インコーポレイテッド Treatment of eye disorders with sirtuin activators
CA2614412A1 (en) 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
CN101268068B (en) 2005-07-19 2015-12-02 阿泽范药品公司 Beta-lactamyl phenylalanine, halfcystine and serine vasopressin antagonists
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
WO2007059307A2 (en) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
US20090075916A1 (en) 2005-11-23 2009-03-19 Upadhyay Dilip J Use of Macrolide Derivatives for Treating Acne
US20090005325A1 (en) 2005-11-23 2009-01-01 Biswajit Bas Ketolide Derivatives as Antibacterial Agents
DOP2006000268A (en) 2005-12-22 2007-07-31 Pfizer Prod Inc ANTIBACTERIAL AGENTS
FR2897154B1 (en) 2006-02-08 2008-03-07 Airbus France Sas DEVICE FOR BUILDING AND SECURING A LOW ALTITUDE FLIGHT PATH TO BE FOLLOWED BY AN AIRCRAFT.
CN101045063B (en) * 2006-03-28 2011-01-26 广州朗圣药业有限公司 Clarithromycin water soluble preparation for injection use
EP2077271A4 (en) 2006-05-01 2010-09-15 Taisho Pharmaceutical Co Ltd MAKROLITDERIVAT
EP2023721A2 (en) 2006-06-05 2009-02-18 Auspex Pharmaceuticals Inc. Preparation and utility of substituted erythromycin analogs
CN101129383B (en) 2006-08-25 2014-04-02 天津和美生物技术有限公司 Antibiotic compound containing aminoglycoside antibiotic
WO2008035222A2 (en) 2006-09-18 2008-03-27 University Of Manitoba Synthesis of carbohydrate-templated amino acids and methods of using same
US8609148B2 (en) 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
JP2010511682A (en) 2006-12-04 2010-04-15 アストラゼネカ アクチボラグ Antibacterial polycyclic urea compounds
JP5025249B2 (en) 2006-12-15 2012-09-12 Ｎｓｋワーナー株式会社 Starting clutch
US20110040078A1 (en) 2007-10-25 2011-02-17 Siegfried Wolf Process for the production of telithromycin
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
US20090209547A1 (en) 2008-02-15 2009-08-20 In Jong Kim C-8 halogenated macrolides
US9072759B2 (en) 2008-10-24 2015-07-07 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
WO2010077730A2 (en) 2008-12-09 2010-07-08 Auspex Pharmaceutical, Inc Indanone inhibitors of acetylcholinesterase
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
US8815831B2 (en) 2009-06-03 2014-08-26 Algipharma As Treatment of Acinetobacter with alginate oligomers and antibiotics
CA2767614C (en) 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
ES2608285T3 (en) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedures for the treatment of malaria, tuberculosis and MAC diseases
PL2544537T3 (en) * 2010-03-10 2017-10-31 Cempra Pharmaceuticals Inc Parenteral formulations of macrolide antibiotics
ES2564097T3 (en) 2010-03-22 2016-03-17 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses thereof
ES2636948T3 (en) 2010-05-20 2017-10-10 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates for them
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US9260473B2 (en) 2010-07-19 2016-02-16 Virginia Commonwealth University Bivalent multifunctional ligands targeting Aβ oligomers as treatment for Alzheimer's disease
CA2812044A1 (en) 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
WO2012042534A2 (en) 2010-09-28 2012-04-05 Glenmark Generics Limited Processes for the preparation of r-sitagliptin and intermediates thereof
JP5718488B2 (en) 2011-03-01 2015-05-13 ウォックハート リミテッド Method for preparing ketolide intermediate
WO2012162439A2 (en) 2011-05-23 2012-11-29 Cem-102 Pharmaceuticals, Inc. Compositions comprising fusidic acid and packages therefor
PT2748165T (en) 2011-08-27 2016-12-28 Wockhardt Ltd 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
AR091790A1 (en) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc DERIVATIVES OF ISOQUINOLIN-1-ONA AND ITS USES
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
IN2014DN08939A (en) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CN105163785A (en) 2013-03-14 2015-12-16 森普拉制药公司 Methods for treating respiratory diseases and formulations therefor
RU2015138797A (en) 2013-03-15 2017-04-24 Семпра Фармасьютикалс, Инк. CONVERGENT METHODS FOR PRODUCING MACROLIDE ANTIBACTERIAL AGENTS
MX377459B (en) 2013-04-04 2025-03-10 Harvard College MACROLIDES AND METHODS FOR THEIR PREPARATION AND USE.
CA2939076A1 (en) 2014-02-14 2015-08-20 Cempra Pharmaceuticals, Inc. Compositions and methods for treating diabetes and liver diseases
CN106660945A (en) 2014-05-27 2017-05-10 迪法玛弗朗西斯有限公司 Azidoalkylamine salts and their use as intermediates
CA2957034A1 (en) 2014-08-05 2016-02-11 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
MX2017011454A (en) 2015-03-06 2018-01-23 Cempra Pharmaceuticals Inc Processes for preparing fluoroketolides.
WO2018045294A1 (en) 2016-09-02 2018-03-08 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides

Also Published As

Publication number Publication date
NZ700182A (en) 2017-02-24
IL254005A0 (en) 2017-10-31
MX2014011537A (en) 2015-02-10
JP6378408B2 (en) 2018-08-22
CA2868262A1 (en) 2013-10-03
CN104470527A (en) 2015-03-25
HK1208622A1 (en) 2016-03-11
KR20140139083A (en) 2014-12-04
SG11201405895UA (en) 2014-10-30
IL254005B (en) 2019-09-26
HK1205939A1 (en) 2015-12-31
JP2018030848A (en) 2018-03-01
EP2830632A4 (en) 2015-10-21
EP2830632A1 (en) 2015-02-04
AU2013239696B2 (en) 2017-12-14
JP6208742B2 (en) 2017-10-04
AU2013239696A1 (en) 2014-10-09
CN104470527B (en) 2019-05-28
WO2013148891A1 (en) 2013-10-03
RU2014139169A (en) 2016-05-20
US20190328759A1 (en) 2019-10-31
AU2013239696C1 (en) 2018-11-29
US10188674B2 (en) 2019-01-29
IL234769A (en) 2017-08-31
RU2658050C2 (en) 2018-06-19
US20150342977A1 (en) 2015-12-03
JP2015512413A (en) 2015-04-27

Similar Documents

Publication Publication Date Title
IN2014DN08939A (en)
MX2017004592A (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs.
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
WO2012054500A3 (en) Compositions for drug administration
MX2009005603A (en) Antibacterial polycyclic urea compounds.
NZ708593A (en) Novel pyrazole derivative
MX2010009163A (en) Heterocyclic urea derivatives and methods of use thereof-211.
UA114906C2 (en) Heterocyclyl compounds
PH12014500386A1 (en) Combination treatment for hepatitis c
MY198204A (en) Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
UA118261C2 (en) Chemical entities
EP4360621A3 (en) Formulations of bendamustine
MX2010013310A (en) Heterocyclic urea derivatives for the treatment of bacterial infections.
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
CY1120602T1 (en) [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES FOR USE IN THE TREATMENT OF MULTIPLATERIC DISEASES
EP4591874A3 (en) Pharmaceutical development
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2022013450A (en) Pharmaceutical formulations.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015014905A (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS.
IN2015DN02109A (en)
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
WO2014184726A3 (en) Compounds and their use in therapy